Insights

Why the Impedimed (ASX:IPD) share price shot higher this morning

The Impedimed share price is shooting higher today, up 5% in morning trade. We take a look at what’s moving the shares.
The post Why the Impedimed (ASX:IPD) share price shot higher this morning appeared first on The Motley Fool Australia. –

man jumps up a chart, indicating share price going up on the ASX bank dividend

The Impedimed Ltd (ASX: IPD) share price shot higher this morning, up 5% in morning trade. 

This came after the ASX medical technology company reported a significant uptick in the number of tests conducted with one of its leading medical devices.

What testing results did Impedimed report?

The Impedimed share price is surging after the company reported its customers had conducted more than 28,000 patient tests with its SOZO device in the second quarter of the 2021 financial year (Q2 FY21). That brings the total number of patient tests since SOZO’s commercial launch in October 2017 to more than 200,000.

The company noted that the pace of testing is picking up speed, with 100,000 tests in the past 13 months compared to the 100,000 tests in the first 32 months. It forecasts the SOZO testing rate will continue to increase.

SOZO is an FDA cleared “non-invasive bioimpedance spectroscopy (BIS) device”. According to the company, the device provides a “precise snapshot of fluid status and tissue composition in less than 30 seconds”. Those results can then be posted directly online, enabling the information to be shared amongst medical professionals.

Management notes

Commenting on the testing numbers, Impedimed CEO Richard Carreon said:

This is a significant milestone for our company, but more importantly for the patients whose lives have been dramatically impacted by the reduction in lymphoedema rates from SOZO testing.

For the company, we are building a large dataset which will be very valuable in providing new insights into the course and care of a large number of chronic disease states.

Carreon added that COVID-19 had seen testing numbers fall in US cancer centres as the pandemic spread in late December and into January. With testing numbers having since improved, he expects testing numbers to pick up in March and that this trend “importantly, points to a strong recovery in patient testing heading into the fourth quarter”.

Impedimed share price snapshot

Over the past full year, the Impedimed shares have gained 44%. That compares to a 10% gain on the All Ordinaries Index (ASX: XAO).

 

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why the Impedimed (ASX:IPD) share price shot higher this morning appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!